Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today released comments by Robert J. Hariri, M.D., Ph.D., ...
The cellular therapy landscape continues to evolve beyond hematologic malignancies, now making significant progress in solid ...
Discover how work cells streamline manufacturing by enhancing efficiency, reducing costs, and minimizing waste, with real-world examples of successful implementation.
Biotechnology firm Cellular Origins, independent organization Cell and Gene Therapy (CGT) Catapult, and biopharmaceutical company Resolution Therapeutics have formed a consortium to deliver a cell ...
Cellular Origins, a TTP Company focused on enabling scalable, cost-effective and efficient manufacture of cell and gene therapies (CGTs) has announced an international collaboration with Thermo Fisher ...
"Interest in private cellular has declined due to budgeting constraints or reprioritization of transformation initiatives, especially amid tariff uncertainties," explains Shadine Taufik, Research ...
Cytiva, and Cellular Origins, have entered into a collaboration designed to revolutionize the manufacture of cell therapies. By combining Cytiva’s automated Sefia platform with Cellular Origin’s ...
STM-01 is aimed at treating severe cardiovascular diseases. Credit: Orawan Pattarawimonchai/Shutterstock. Cellipont Bioservices and Secretome Therapeutics are set to ...
Cellipont Bioservices, a cell therapy Contract Development and Manufacturing Organization (CDMO), and Secretome Therapeutics, a biotechnology company advancing therapies derived from neonatal cardiac ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback